体外膜肺氧合辅助治疗下儿童重症患者抗感染治疗方案的优化研究进展
|
摘要
<正>体外膜肺氧合(extracorporeal membrane oxygenation,ECMO)是一种可经皮置入的机械循环辅助技术,具有置入方便、不受地点限制的优点,近年来越来越多地用于常规生命支持无效的各种急性循环和/或呼吸衰竭重症患者的辅助治疗[1]。据中国生物医学工程学会体外循环分会统计,2016年我国有1234例患者接受了ECMO辅助治疗[2]。在儿科领域,ECMO被广泛应用于暴发性心肌炎、急性呼吸窘迫综合征等重症患者中[3]。当然,对于重症患儿而言,仅靠ECMO辅助治疗
引文
[1]中国医师协会体外生命支持专业委员会.成人体外膜氧合循环辅助专家共识[J].中华医学杂志,2018,98(12):886-894.
[2]黑飞龙,朱德明,侯晓彤,等.2016年中国心脏外科手术和体外循环数据白皮书[J].中国体外循环杂志,2017,15(2):65-67.
[3]张军.体外膜肺氧合治疗儿童重症心肌炎的研究进展[J].中国循环杂志,2017,32(11):1128-1130.
[4]SHEKAR K,MULLANY D V,THOMSON B,et al.Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients:a comprehensive review[J].Crit Care,2014,18(3):219.
[5]WILDSCHUT E D,AHSMAN M J,ALLEGAERT K,et al.Determinants of drug absorption in different ECMO circuits[J].Intensive Care Med,2010,36(12):2109-2116.
[6]SHEKAR K,ROBERTS J A,MCDONALD C I,et al.Proteinbound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit:results from an ex vivo study[J].Crit Care,2015,19:164.
[7]SHEKAR K,FRASER J F,SMITH M T,et al.Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation[J].J Crit Care,2012,27(6):741.e9-18.
[8]ULLDEMOLINS M,ROBERTS J A,LIPMAN J,et al.Antibiotic dosing in multiple organ dysfunction syndrome[J].Chest,2011,139(5):1210-1220.
[91]LEVEN C,FILLATRE P,PETITCOLLIN A,et al.Ex vivomodel to decipher the impact of extracorporeal membrane oxygenation on beta-lactam degradation kinetics[J].Ther Drug Moni,2017,39(2):180-184.
[10]AHSMAN M J,WILDSCHUT E D,TIBBOEL D,et al.Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation[J].Antimicrob Agents Chemother,2010,54(5):1734-1741.
[11]中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志,2018,41(6):409-445.
[12]CIES J J,MOORE W S 2nd,CALAMAN S,et al.Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient[J].Pharmacotherapy,2015,35(4):e32-36.
[13]HANBERG P,OBRINK-HANSEN K,THORSTED A,et al.Population pharmacokinetics of meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment[J].Antimicrob Agents Chemother,2018,62(5):e02390-17.
[14]SHEKAR K 1,ROBERTS J A,WELCH S,et al.ASAP ECMO:antibiotic,sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation:a multicentre study to optimise drug therapy during ECMO[J].BMC Anesthesiol,2012,12:29.
[15]BHATT-MEHTA V,JOHNSON C E,SCHUMACHER R E.Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation[J].Pharmacotherapy,1992,12(1):28-32.
[16]SHERWIN J,HEATH T,WATT K.Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation:a review of the current literature[J].Clin Ther,2016,38(9):1976-1994.
[17]MOFFETT B S,MORRIS J,GALATI M. Population pharmacokinetic analysis of gentamicin in pediatric extracorporeal membrane oxygenation[J].Ther Drug Monit,2018,40(5):581-588.
[18]GELISSE E,NEUVILLE M,DE MONTMOLLIN E,et al.Extracorporeal membrane oxygenation(ECMO)does not impact on amikacin pharmacokinetics:a case-control study[J].Intensive Care Med,2016,42(5):946-948.
[19]ABDUL-AZIZ M H,SHEKAR K,ROBERTS J A.Antibiotic dosing during extracorporeal membrane oxygenation[M].//UDY A,ROBERTS J,LIPMAN J.Antibiotic pharmacokinetic/pharmacodynamic considerations in the critically III.Adis,Singapore:151-171.
[20]徐思露,邵华,胡琳璘,等.体外膜肺氧合对抗菌药物药代动力学影响的研究进展[J].中国临床药理学杂志,2017,33(4):376-380.
[21]DI NARDO M,WILDSCHUT E D.Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics[J].J Thorac Dis,2018,10(Suppl 5):S642-S652.
[22]ZYLBERSZTAJN B L,IZQUIERDO G,SANTANA R C,et al.Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support[J].J Pediatr Pharmacol Ther,2018,23(4):305-310.
[23]BUCK M L.Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation[J].Pharmacotherapy,1998,18(5):1082-1086.
[24]DONADELLO K,ROBERTS J A,CRISTALLINI S,et al.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy:a matched cohort study[J].Crit Care,2014,18(6):632.
[25]PATEL K,CRUMBY A S,MAPLES H D.Balancing vancomycin efficacy and nephrotoxicity:should we be aiming for trough or AUC/MIC?[J].Paediatr Drugs,2015,17(2):97-103.
[26]WILDSCHUT E D,AHSMAN M J,HOUMES R J,et al.Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation(ECMO)[J].Curr Drug Metab,2012,13(6):767-777.
[27]WILDSCHUT E D,DE HOOG M D,AHSMAN M J,et al.Plasma concentrations of oseltamivir and oseltamivir carboxylate in criticallyⅢchildren on extracorporeal membrane oxygenation support[J].PLoS One,2010,5(6):e10938.
[28]EYLER R F,KLEIN K C,MUELLER B A.The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis[J].J Pediat Pharmacol Ther,2012,17(2):173-176.
[29]SARGEL C L,ABOUD M,FORSTER A,et al.Intravenous ribavirin for parainfluenza and respiratory syncytial virus in an infant receiving extracorporeal membrane oxygenation and continuous renal replacement therapy[J].J Pediatr Pharmacol Ther,2018,23(4):337-342.
[30]WISHART D S,KNOX C,GUO A C,et al.DrugBank:a comprehensive resource for in silico drug discovery and exploration[J].Nucleic Acids Res,2006,34(Database issue):668-672.
[31]BRUGGEMANN R J,ANTONIUS T,HEIJST A V,et al.Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation[J].Ther Drug Monit,2008,30(6):643-646.
[32]RUIZ S,PAPY E,DA SILVA D,et al.Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation[J].Intensive Care Med,2009,35(1):183-184.
[33]SPRIET I,ANNAERT P,MEERSSEMAN P,et al.Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation[J].J Antimicrob Chemother,2009,63(4):767-770.
[34]KOCH B C,WILDSCHUT E D,GOEDE A L,et al.Insufficient serum caspofungin levels in a paediatric patient on ECMO[J].Med Mycol Case Rep,2013,2:23-24.
[2]黑飞龙,朱德明,侯晓彤,等.2016年中国心脏外科手术和体外循环数据白皮书[J].中国体外循环杂志,2017,15(2):65-67.
[3]张军.体外膜肺氧合治疗儿童重症心肌炎的研究进展[J].中国循环杂志,2017,32(11):1128-1130.
[4]SHEKAR K,MULLANY D V,THOMSON B,et al.Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients:a comprehensive review[J].Crit Care,2014,18(3):219.
[5]WILDSCHUT E D,AHSMAN M J,ALLEGAERT K,et al.Determinants of drug absorption in different ECMO circuits[J].Intensive Care Med,2010,36(12):2109-2116.
[6]SHEKAR K,ROBERTS J A,MCDONALD C I,et al.Proteinbound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit:results from an ex vivo study[J].Crit Care,2015,19:164.
[7]SHEKAR K,FRASER J F,SMITH M T,et al.Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation[J].J Crit Care,2012,27(6):741.e9-18.
[8]ULLDEMOLINS M,ROBERTS J A,LIPMAN J,et al.Antibiotic dosing in multiple organ dysfunction syndrome[J].Chest,2011,139(5):1210-1220.
[91]LEVEN C,FILLATRE P,PETITCOLLIN A,et al.Ex vivomodel to decipher the impact of extracorporeal membrane oxygenation on beta-lactam degradation kinetics[J].Ther Drug Moni,2017,39(2):180-184.
[10]AHSMAN M J,WILDSCHUT E D,TIBBOEL D,et al.Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation[J].Antimicrob Agents Chemother,2010,54(5):1734-1741.
[11]中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志,2018,41(6):409-445.
[12]CIES J J,MOORE W S 2nd,CALAMAN S,et al.Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient[J].Pharmacotherapy,2015,35(4):e32-36.
[13]HANBERG P,OBRINK-HANSEN K,THORSTED A,et al.Population pharmacokinetics of meropenem in plasma and subcutis from patients on extracorporeal membrane oxygenation treatment[J].Antimicrob Agents Chemother,2018,62(5):e02390-17.
[14]SHEKAR K 1,ROBERTS J A,WELCH S,et al.ASAP ECMO:antibiotic,sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation:a multicentre study to optimise drug therapy during ECMO[J].BMC Anesthesiol,2012,12:29.
[15]BHATT-MEHTA V,JOHNSON C E,SCHUMACHER R E.Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation[J].Pharmacotherapy,1992,12(1):28-32.
[16]SHERWIN J,HEATH T,WATT K.Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation:a review of the current literature[J].Clin Ther,2016,38(9):1976-1994.
[17]MOFFETT B S,MORRIS J,GALATI M. Population pharmacokinetic analysis of gentamicin in pediatric extracorporeal membrane oxygenation[J].Ther Drug Monit,2018,40(5):581-588.
[18]GELISSE E,NEUVILLE M,DE MONTMOLLIN E,et al.Extracorporeal membrane oxygenation(ECMO)does not impact on amikacin pharmacokinetics:a case-control study[J].Intensive Care Med,2016,42(5):946-948.
[19]ABDUL-AZIZ M H,SHEKAR K,ROBERTS J A.Antibiotic dosing during extracorporeal membrane oxygenation[M].//UDY A,ROBERTS J,LIPMAN J.Antibiotic pharmacokinetic/pharmacodynamic considerations in the critically III.Adis,Singapore:151-171.
[20]徐思露,邵华,胡琳璘,等.体外膜肺氧合对抗菌药物药代动力学影响的研究进展[J].中国临床药理学杂志,2017,33(4):376-380.
[21]DI NARDO M,WILDSCHUT E D.Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics[J].J Thorac Dis,2018,10(Suppl 5):S642-S652.
[22]ZYLBERSZTAJN B L,IZQUIERDO G,SANTANA R C,et al.Therapeutic drug monitoring of vancomycin in pediatric patients with extracorporeal membrane oxygenation support[J].J Pediatr Pharmacol Ther,2018,23(4):305-310.
[23]BUCK M L.Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation[J].Pharmacotherapy,1998,18(5):1082-1086.
[24]DONADELLO K,ROBERTS J A,CRISTALLINI S,et al.Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy:a matched cohort study[J].Crit Care,2014,18(6):632.
[25]PATEL K,CRUMBY A S,MAPLES H D.Balancing vancomycin efficacy and nephrotoxicity:should we be aiming for trough or AUC/MIC?[J].Paediatr Drugs,2015,17(2):97-103.
[26]WILDSCHUT E D,AHSMAN M J,HOUMES R J,et al.Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation(ECMO)[J].Curr Drug Metab,2012,13(6):767-777.
[27]WILDSCHUT E D,DE HOOG M D,AHSMAN M J,et al.Plasma concentrations of oseltamivir and oseltamivir carboxylate in criticallyⅢchildren on extracorporeal membrane oxygenation support[J].PLoS One,2010,5(6):e10938.
[28]EYLER R F,KLEIN K C,MUELLER B A.The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis[J].J Pediat Pharmacol Ther,2012,17(2):173-176.
[29]SARGEL C L,ABOUD M,FORSTER A,et al.Intravenous ribavirin for parainfluenza and respiratory syncytial virus in an infant receiving extracorporeal membrane oxygenation and continuous renal replacement therapy[J].J Pediatr Pharmacol Ther,2018,23(4):337-342.
[30]WISHART D S,KNOX C,GUO A C,et al.DrugBank:a comprehensive resource for in silico drug discovery and exploration[J].Nucleic Acids Res,2006,34(Database issue):668-672.
[31]BRUGGEMANN R J,ANTONIUS T,HEIJST A V,et al.Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation[J].Ther Drug Monit,2008,30(6):643-646.
[32]RUIZ S,PAPY E,DA SILVA D,et al.Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation[J].Intensive Care Med,2009,35(1):183-184.
[33]SPRIET I,ANNAERT P,MEERSSEMAN P,et al.Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation[J].J Antimicrob Chemother,2009,63(4):767-770.
[34]KOCH B C,WILDSCHUT E D,GOEDE A L,et al.Insufficient serum caspofungin levels in a paediatric patient on ECMO[J].Med Mycol Case Rep,2013,2:23-24.